CONTINUE TO SITE ➞
Isomorphic Labs recently raked in $600 million to help develop its drug discovery platform.Read more➔
The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.
This technology brings both benefits and drawbacks for the field, which is also testing alternatives.
The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.
After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma giants are even more ambitious for the next wave of biologic medicines.
Along with shrinking the HHS’ workforce further, the reorganization announced Thursday will cut the department from 28 divisions to 15, and close five regional offices.
A delay of the prescription-to-OTC rule signals health agencies’ ongoing reluctance to implement new regulations.
As it returns from the brink, the vaccine developer has brought in Dr. Ruxandra Draghia-Akli — and her industry and public health chops — to lead R&D.
The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.
The FDA delisted semaglutide and tirzepatide from its shortage list, putting an end to copycat GLP-1s.
The companies are striving to bring fresh innovations to cancer care, pain management and the weight loss space.
Pharma has long been considered “recession proof,” but an economic downturn could still hurt the industry in numerous ways.
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also enduring tragic risk.
Chinese companies are involved in one-fifth of pharma’s clinical development programs, but trade wars and regulatory hurdles could stymie dealmaking.
A handful of states are targeting the technology at the same time the Trump administration is cutting research funding and revoking vaccine contracts.
Smaller biotechs are finding creative ways to fund R&D at a time when the traditional financing channels have become more constrictive.
Even with Big Pharmas pouring billions into the space, the potential of radiopharmaceuticals remains largely untapped.
The new $5.3 billion deal with the Swiss pharma giant gives Zealand a significant partner to advance its amylin analog obesity shot and create a new combination product.
The pharma giant announced a new partnership with BridGene Biosciences that will use its IMTAC platform for drug discovery.
HHS head Robert F. Kennedy Jr. has long been an opponent of pharma influence in government. U.S. lawmakers are asking whether unofficial Mar-a-Lago meetings point to a change of heart.
Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.
Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can efforts to bring transparency into that system now pan out?
Familiar foes in the industry have claimed a slew of jobs in recent months.
Experts say cost and other barriers present challenges to returning to U.S. shores.
With President Trump’s nominee for FDA commissioner in Senate confirmation hearings, his approach to workforce cuts and other policies is under scrutiny.
Subscribe to PharmaVoice for important stories, insights & perspectives
Get the free daily newsletter read by industry leaders
